Biopharmaceutical News and Research

RSS

AANS, CNS urge CMS to finalize rules to improve prior authorization

Today, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) joined 61 bipartisan senators and 233 members of the House of Representatives in urging the U.S. Department of Health and Human Services and Centers for Medicare & Medicaid Services (CMS) to swiftly finalize rules to increase transparency, streamline and standardize prior authorization (PA).

4 Jul 2023

Multiple drug targets for the treatment of influenza identified using AI program

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence ('AI') Programme with CytoReason.

1 Jul 2023

Four pancreatic injury safety biomarkers identified and evaluated by PSTC

Critical Path Institute (C-Path) today announced that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA) issued a Biomarker Letter of Support (LOS) for four pancreatic injury safety biomarkers identified and evaluated by C-Path's Predictive Safety Testing Consortium's (PSTC) Pancreatic Injury Working Group (PIWG).

14 Jun 2023

Keynote speakers of ELRIG Drug Discovery 2023 announced

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the keynote speakers for Drug Discovery 2023, taking place at the ACC in Liverpool from 18–19 October. Prof Janet Hemingway CBE, FRS, Founding Director of Infection Innovation Consortium (iiCON), and Dr Dave Powell, Chief Scientific Officer (CSO) of LifeArc will lead this year’s event focussing on diverse thinking and new perspectives.

10 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.

8 Jun 2023

ELRIG UK Announces Prof Janet Hemingway and Dr Dave Powell as Keynote Speakers at Drug Discovery 2023

ELRIG Drug Discovery 2023 at ACC Liverpool (18–19 October) to focus on diverse thinking and new perspectives.

From ELRIG (UK) Ltd. 6 Jun 2023

Eye drops to slow the progression of nearsightedness in kids could be on the horizon

The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon.

1 Jun 2023

Dutch scientists unveil the integral role of CD5L protein in IgM structure and function

Researchers in the Netherlands assessed the structure of human circulatory IgM and its relationship with the small CD5L protein.

31 May 2023

Survey reveals the limited knowledge about actinic keratosis among most people

Almirall S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, presented today the results of a survey revealing that 85% of respondents are unaware of the existence of actinic keratosis (AK).

25 May 2023

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration's push for lower drug prices at the pharmacy counter.

22 May 2023

Valbenazine improves chorea associated with Huntington's disease

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

19 May 2023

Nemours Children's Health selected to conduct first gene therapy clinical trial for Morquio A syndrome

As part of the Foundation for the National Institutes of Health Accelerating Medicines Partnership Bespoke Gene Therapy Consortium, Nemours Children's Health has been chosen to conduct a first-of-its-kind gene therapy clinical trial for Morquio A syndrome.

16 May 2023

Gyros Protein Technologies introduces Gyrolab Generic Cyno ADA Kit Reagents to support pre-clinical immunogenicity assessment

Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

From Gyros Protein Technologies AB 4 May 2023

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors.

From Sphere Fluidics 2 May 2023

Novel immunotherapy appears to be safe, well tolerated by children with relapsed brain tumors

The first in-human-study of a new immunotherapy that blocks a natural enzyme tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.

25 Apr 2023

Biopharmaceutical News and Research

AANS, CNS urge CMS to finalize rules to improve prior authorization

Multiple drug targets for the treatment of influenza identified using AI program

Four pancreatic injury safety biomarkers identified and evaluated by PSTC

Keynote speakers of ELRIG Drug Discovery 2023 announced

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

ELRIG UK Announces Prof Janet Hemingway and Dr Dave Powell as Keynote Speakers at Drug Discovery 2023

Eye drops to slow the progression of nearsightedness in kids could be on the horizon

Dutch scientists unveil the integral role of CD5L protein in IgM structure and function

Survey reveals the limited knowledge about actinic keratosis among most people

A more aggressive FTC is starting to target drug mergers and industry middlemen

Valbenazine improves chorea associated with Huntington's disease

Nemours Children's Health selected to conduct first gene therapy clinical trial for Morquio A syndrome

Gyros Protein Technologies introduces Gyrolab Generic Cyno ADA Kit Reagents to support pre-clinical immunogenicity assessment

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Novel immunotherapy appears to be safe, well tolerated by children with relapsed brain tumors

Combination treatment could improve stem cell transplantation process for multiple myeloma patients

Using tiny bubbles to improve gene therapy

Modified Botox can alleviate chronic pain without risk of paralysis or addiction

Riboswitch may be the key to advance gene therapy, regenerative medicine

How to optimize your cell line development eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News